Could a single cell infusion replace lifelong Anti-Rejection drugs?
NCT ID NCT03726307
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests whether a single infusion of special immune cells (regulatory dendritic cells) from the kidney donor can help the recipient's body accept the new kidney with fewer side effects. 14 first-time kidney transplant recipients will receive the cells one week before surgery and be followed for two years. The main goal is to check safety, not yet to prove the treatment works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Pittsburgh, Starzl Transplantation Institute
Pittsburgh, Pennsylvania, 15213, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug work safely in patients with kidney failure?
- Could the choice of anesthesia quiet the Body's surgical stress response?
- A simple blood test could spot kidney transplant rejection early
- Can your gut bacteria change how transplant drugs work?
- What does life feel like for children with a rare birth defect? a new study asks
- AI therapy coach aims to ease distress in seriously ill seniors